Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC
Recruiting · NCT07769827 · Registry updated 2026-08-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC | HBV-HCC; Unresectable Advanced HBV-related Liver Cancer | Recruiting | Not applicable | 2026-08-18 | NCT07769827 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jinling Hospital, China | 33 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Jinling Hospital, Nanjing University Medical School | Nanjing | China | 1 |